BACKGROUND AND PURPOSE: Endocannabinoids in tissues controlling energy homeostasis are altered in obesity, thus contributing to metabolic disorders. Here we evaluate endocannabinoid dysregulation in the small intestine of mice with diet-induced obesity (DIO) and in peripheral tissues of Zucker and lean rats following food deprivation and re-feeding. EXPERIMENTAL APPROACH: Intestinal transit, evaluated using rhodamine-B-labelled dextran, and small intestinal endocannabinoid levels, measured by liquid chromatography mass spectrometry, were measured in mice fed normal or high-fat diets (HFDs). Endocannabinoid levels were measured also in various tissues of lean and Zucker rats fed ad libitum or following overnight food deprivation with and without subsequent re-feeding. KEY RESULTS: After 8 weeks of HFD, baseline intestinal transit was increased in DIO mice and enhanced by cannabinoid CB(1) receptor antagonism less efficaciously than in lean mice. Small intestinal anandamide and 2-arachidonoylglycerol levels were reduced and increased respectively. In Zucker rats, endocannabinoids levels were higher in the pancreas, liver and duodenum, and lower in the subcutaneous adipose tissue. Food deprivation increased endocannabinoid levels in the duodenum and liver of both rat strains, in the pancreas of lean rats and in adipose tissues of Zucker rats. CONCLUSIONS AND IMPLICATIONS: Reduced anandamide levels might account for increased intestinal motility in DIO mice. Regulation of endocannabinoid levels in rat peripheral tissues, induced by food deprivation and re-feeding, might participate in food intake and energy processing and was altered in Zucker rats. These data, together with previous observations, provide further evidence for dysregulation of peripheral endocannabinoids in obesity.
BACKGROUND AND PURPOSE:Endocannabinoids in tissues controlling energy homeostasis are altered in obesity, thus contributing to metabolic disorders. Here we evaluate endocannabinoid dysregulation in the small intestine of mice with diet-induced obesity (DIO) and in peripheral tissues of Zucker and lean rats following food deprivation and re-feeding. EXPERIMENTAL APPROACH: Intestinal transit, evaluated using rhodamine-B-labelled dextran, and small intestinal endocannabinoid levels, measured by liquid chromatography mass spectrometry, were measured in mice fed normal or high-fat diets (HFDs). Endocannabinoid levels were measured also in various tissues of lean and Zucker rats fed ad libitum or following overnight food deprivation with and without subsequent re-feeding. KEY RESULTS: After 8 weeks of HFD, baseline intestinal transit was increased in DIO mice and enhanced by cannabinoid CB(1) receptor antagonism less efficaciously than in lean mice. Small intestinal anandamide and 2-arachidonoylglycerol levels were reduced and increased respectively. In Zucker rats, endocannabinoids levels were higher in the pancreas, liver and duodenum, and lower in the subcutaneous adipose tissue. Food deprivation increased endocannabinoid levels in the duodenum and liver of both rat strains, in the pancreas of lean rats and in adipose tissues of Zucker rats. CONCLUSIONS AND IMPLICATIONS: Reduced anandamide levels might account for increased intestinal motility in DIO mice. Regulation of endocannabinoid levels in rat peripheral tissues, induced by food deprivation and re-feeding, might participate in food intake and energy processing and was altered in Zucker rats. These data, together with previous observations, provide further evidence for dysregulation of peripheral endocannabinoids in obesity.
Authors: F J Bermúdez-Silva; J Suárez; E Baixeras; N Cobo; D Bautista; A L Cuesta-Muñoz; E Fuentes; P Juan-Pico; M J Castro; G Milman; R Mechoulam; A Nadal; F Rodríguez de Fonseca Journal: Diabetologia Date: 2007-12-19 Impact factor: 10.122
Authors: Carol Addy; Hamish Wright; Koen Van Laere; Ira Gantz; Ngozi Erondu; Bret J Musser; Kaifeng Lu; Jinyu Yuan; Sandra M Sanabria-Bohórquez; Aubrey Stoch; Cathy Stevens; Tung M Fong; Inge De Lepeleire; Caroline Cilissen; Josee Cote; Kim Rosko; Isaias N Gendrano; Allison Martin Nguyen; Barry Gumbiner; Paul Rothenberg; Jan de Hoon; Guy Bormans; Marleen Depré; Wai-si Eng; Eric Ravussin; Samuel Klein; John Blundell; Gary A Herman; H Donald Burns; Richard J Hargreaves; John Wagner; Keith Gottesdiener; John M Amatruda; Steven B Heymsfield Journal: Cell Metab Date: 2008-01 Impact factor: 27.287
Authors: I Matias; M-P Gonthier; S Petrosino; L Docimo; R Capasso; L Hoareau; P Monteleone; R Roche; A A Izzo; V Di Marzo Journal: Br J Pharmacol Date: 2007-08-20 Impact factor: 8.739
Authors: N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; K A Sharkey Journal: Br J Pharmacol Date: 2010-10 Impact factor: 8.739
Authors: Mónica Alonso; Antonia Serrano; Margarita Vida; Ana Crespillo; Laura Hernandez-Folgado; Nadine Jagerovic; Pilar Goya; Carmen Reyes-Cabello; Vidal Perez-Valero; Juan Decara; Manuel Macías-González; Francisco Javier Bermúdez-Silva; Juan Suárez; Fernando Rodríguez de Fonseca; Francisco Javier Pavón Journal: Br J Pharmacol Date: 2012-04 Impact factor: 8.739
Authors: Angela M Gajda; Yin Xiu Zhou; Luis B Agellon; Susan K Fried; Sarala Kodukula; Walter Fortson; Khamoshi Patel; Judith Storch Journal: J Biol Chem Date: 2013-08-29 Impact factor: 5.157